Uramoto Hidetaka, Sugio Kenji, Oyama Tsunehiro, Nakata Shoji, Ono Kenji, Morita Masaru, Funa Keiko, Yasumoto Kosei
Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Clin Cancer Res. 2004 Oct 15;10(20):6905-11. doi: 10.1158/1078-0432.CCR-04-0290.
DeltaNp73 is an isoform of the p53 homologue p73, which lacks an NH(2)-terminal transactivation domain and antagonizes the induction of gene expression by p53/p73. The aim of this study was to detect DeltaNp73 expression in lung cancer and to evaluate the relationship between the DeltaNp73 expression level and the prognosis of patients with resected lung cancer.
We used immunohistochemistry to analyze the protein expression of DeltaNp73 in paraffin-embedded tumor samples from 132 well-characterized lung cancer patients and compared the expression level of DeltaNp73, clinical variables, and survival outcome.
Positive expression of DeltaNp73 was detected mainly in the cytoplasm of tumor cells in 77 of 132 patients (58.3%) with lung cancer. The incidence of positive expression of DeltaNp73 was 52.2, 50.0, and 70.2% in patients with stage I, II, and III, respectively (P = 0.04). Positive expression of DeltaNp73 was associated with gender but not associated with age, histologic type, pathological stage, pathological T status, and pathological N status. Lung cancer patients with positive DeltaNp73 expression had a poorer prognosis than those with negative DeltaNp73 expression. In addition, multivariate analysis of the clinicopathological characteristics of lung cancer indicated that positive expression of DeltaNp73 was a significant independent factor for predicting poor prognosis (P < 0.0001, risk ratio = 3.39).
Expression of DeltaNp73 may be a useful marker for predicting poor prognosis of patients who underwent resection of lung cancer.
DeltaNp73是p53同源物p73的一种异构体，它缺乏氨基末端反式激活结构域，并拮抗p53/p73诱导的基因表达。本研究的目的是检测DeltaNp73在肺癌中的表达，并评估DeltaNp73表达水平与肺癌切除患者预后之间的关系。
我们采用免疫组织化学方法分析了132例特征明确的肺癌患者石蜡包埋肿瘤样本中DeltaNp73的蛋白表达，并比较了DeltaNp73的表达水平、临床变量和生存结果。
132例肺癌患者中有77例（58.3%）的肿瘤细胞胞质中检测到DeltaNp73阳性表达。I期、II期和III期患者中DeltaNp73阳性表达的发生率分别为52.2%、50.0%和70.2%（P = 0.04）。DeltaNp73阳性表达与性别有关，但与年龄、组织学类型、病理分期、病理T状态和病理N状态无关。DeltaNp73表达阳性的肺癌患者预后比DeltaNp73表达阴性的患者差。此外，对肺癌临床病理特征的多因素分析表明，DeltaNp73阳性表达是预测预后不良的一个重要独立因素（P < 0.0001，风险比 = 3.39）。
DeltaNp73的表达可能是预测肺癌切除患者预后不良的一个有用标志物。
